The San Diego-based insulin delivery and diabetes technology company posted losses of -$9.4 million, or -15¢ per share, on sales of $123.6 million for the three months ended Sept.30, 2020, for a bottom-line slide to remain in the red despite sales growth of 30.1%.
IN CASE YOU MISSED IT
- Canada approves Tandem Diabetes Caree’s advanced hybrid closed-loop insulin pump
- Appeals court nixes GSK’s petition for new trial in Vectura patent spat
- Lilly and Ypsomed team up on automated insulin delivery
- Key steps for medical device manufacturers effective CAPA management
- Alaris remediation could cost BD up to $244M